Transdermal oestradiol gel in the treatment of the climacterium: A comparison with oral therapy

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 104, Issue , 1997, Pages 19-25

  Hirvonen, E ^a   Lamberg Allardt, C ^b   Lankinen, K S ^c   Geurts, P ^d   Wilen Rosenqvist G ^c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c ORION CORPORATION   (Finland)

^d NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG;

ADULT; AGED; BLEEDING; BONE TURNOVER; CLIMACTERIUM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ESTROGEN DEFICIENCY; FEMALE; FINLAND; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; BONE DENSITY; CHOLESTEROL; CLIMACTERIC; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GELS; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PROGESTERONE CONGENERS; SWEATING; TREATMENT REFUSAL; UTERINE HEMORRHAGE;

EID: 0030775122     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1997.tb11563.x     Document Type: Article

References (20)

1. Scott RT, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: A crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstel Gynecol 1991; 77: 758–764.
2. Nachtigall LE. Emerging delivery systems for estrogen replacement: Aspects of transdermal and oral delivery. Am J Obstel Gynecol 1995; 173: 993–997.
3. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994; 71: 420–423.
4. O’Connel MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995; 35: 18S–24S.
5. Hirvonen E, Mälkönen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981; 304: 560–563.
6. Ettinger B. Use of low-dosage 17β-estradiol for the prevention of osteoporosis. Clin Ther 1993; 15: 950–962.
7. Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166: 479–488.
8. Dupont A, Dupont P, Cusan L, Tremblay M, Rioux J, Cloutier D et al. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991; 13: 297–311.
9. Kornafel KL, March CM. Estradiol gel in the treatment of menopausal symptoms: A placebo-controlled double-blind case study of efficacy and safety. South Med J 1992; 85: 270–273.
10. Backstrom A-C, Hirvonen E, Kivinen S. Efficacy and skin irritation with two forms of transdermal estrogen therapy. In: Abstract Book of 8th International Congress on the Menopause, 37 November 1996, Sydney, Australia, p. 151.
11. Balfour JA, McTavish D. Transdermal Estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis. Drugs Aging 1992; 6: 487–507.
12. Riis BJ, Thomsen K, Strøm V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987; 156: 61–65.
13. Hillard TC, Whitcroft SJ, Marsh MS, Ellerington MC. Lees B, Whitehead MI. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone Loss. Osteoporosis Int 1994; 4: 341–348.
14. Palacios S, Menéndez C. Jurado AR, Vargas JC. Effects of percutaneous oestradiol versus oral oestrogens on bone density. Maturitas 1995: 20: 209–213.
15. Hoof HJC van, Mooren MJ van der, Swinkels LMJW, Rolland R, Benraad TJ. Hormone replacement therapy increases scrum 1,25- dihydroxyvitamin D: A 2-year prospective study. Calcif Tissue 1994; 55: 417–419.
16. Cheang A, Sitruk-Ware R, Samsioe G. Transdermal oestradiol and cardiovascular risk factors. Br J Obstet Gynaecol 1994; 101: 571–581.
17. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208.
18. LaRosa JC. Has HRT come of age? (Editorial). Lancet 1995; 345: 76–77.
19. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system. Nonlipid effects. Drugs 1994; 47(Suppl. 2): 35–41.
20. Holst J. Percutaneous estrogen therapy. Endometrial response and metabolic effects. Acta Obstet Gynecol Scand 1983; Suppl 115: 7–30.